FDA 483 OBSERVATION · #28 OF 1,923 MOST-CITED
Lack of or inadequate process validation
FDA cited this observation 772 times across 673 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
A process whose results cannot be fully verified by later inspection or test was not validated with a high degree of assurance, or the validation was inadequate — insufficient challenge, missing acceptance criteria, or no ongoing monitoring to show the process stays in control.
Why FDA writes it — When you cannot test quality into every unit, you must build it in through a validated process. Inadequate validation means the firm is relying on hope that the process performs — exactly the situation the requirement exists to prevent.
- Validate processes whose output cannot be fully verified by subsequent inspection and test, with documented protocols, defined acceptance criteria, and a high degree of assurance.
- Challenge the process across its intended operating range and worst-case conditions, not just nominal runs.
- Establish ongoing process monitoring / continued process verification so a validated state is maintained, not just achieved once.
- Revalidate after changes to the process, equipment, or materials that could affect the output.
- Validation treated as a one-time qualification event rather than a lifecycle with continued verification.
- Protocols that confirm the process runs on a good day but never challenge its edges or worst case.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.8× the rate of the average FDA-cited firm (13.7% vs 7.8%), across 673 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures.
A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures.
A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures.
A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures.
A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures.
A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →